Medical Directorate, National Kidney Foundation, Singapore

Slides:



Advertisements
Similar presentations
Relapse in Children with ALL By Dr Kaji Protocol for Acute Lymphoblastic Leukemia Relapse IN LANZKOWSKY.
Advertisements

Update of Anemia management in chronic kidney disease What is still missing.
1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.
Anemia in chronic kidney disease
Iron Repletion in ESRD Saleem Bharmal 2/9/10.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.
Clinical Experience With Antibiotic Protocol & RSD N=22 Duration of treatment: 2-4 months Retrospective, open label, clinical trial Responses are based.
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
Pharmacy 483 Outcomes & Cost Management in Pharmacy Practice Janet Kelly, Pharm.D., BC-ADM February 24, 2004.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
Carla Chieffo, David Cook, Qinfang Xiang, and Lawrence A. Frohman Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly.
Iron as a Treatment: Successes and Failures. What next? Christopher J Earley MB, BCh, PhD, FRCP(I) Professor Department of Neurology Johns Hopkins School.
The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson.
Abstract Results Effects of Iron Therapy on Pituitary Gonadal Axis and Sperm Parameters in Adults with Iron Deficiency Anemia (IDA). Ashraf T. Soliman,
Aetiology of preoperative anaemia in patients undergoing elective cardiac surgery Jacob Abhrahm 1,Romi Sinha 2,Kathryn Robinson 3, David Cardone 1 1 Department.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
ALBUMIN IS AN EFFECT MODIFIER IN THE RELATIONSHIP BETWEEN ERYTHROPOIETIN STIMULATING AGENT AND MORTALITY IN HEMODIALYSIS PATIENTS. Satoshi Mikami1, Takayuki.
Cost conscious project: Microcytic anemia
Mansoura International Hospital Mansoura International Hospital
Algorithm for management of anemia of CKD in adults
Copyright © 2002 American Medical Association. All rights reserved.
Sergey V. Veretennikov and Michael J. Campbell, MD
Luisa Sandri, MD, and Martino Marangella, MD
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label,
Chapter 2: Clinical Indicators and Preventive Care
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
Iron indices: What do they really mean?
New and Emerging Management Options for Anemia in CKD
Are we giving too much iron
A. Besarab  Kidney International  Volume 69, Pages S13-S18 (May 2006)
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Iron status and iron supplementation in peritoneal dialysis patients
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.
Addressing Iron Deficiency in Chronic HF
Iron Deficiency Anemia
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients  Jiacong Luo, MD, MS, MPH, Donna E.
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A
A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients.
L. A. den Otter. , R. M. Anakotta. , M. Dieters. , C. T. Muijs. , S
Obstacles and Advances in Anemia Management in Patients With CKD
Volume 2: End-Stage Renal Disease
Volume 64, Pages S72-S77 (November 2003)
Volume 88, Issue 5, Pages (November 2015)
Use of Periodic Intravenous Iron Sucrose for Routine Iron Supplementation in Children with Inflammatory Bowel Disease Istvan Danko, MD, PhD Department.
Chen S, Dong Y, Kiuchi MG, et al
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label,
Iron Deficiency Anemia
Volume 54, Issue 2, Pages (August 1998)
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Managing Anemia in Lower-Risk MDS
Joseph W. Eschbach, John W. Adamson  Kidney International 
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 60, Issue 6, Pages (December 2001)
Volume 68, Issue 6, Pages (December 2005)
Recent experience with high-dose intravenous iron administration
Volume 64, Pages S72-S77 (November 2003)
Volume 79, Issue 3, Pages (February 2011)
Volume 67, Issue 6, Pages (June 2005)
Erythropoietin and iron
Volume 55, Issue 5, Pages (May 1999)
Volume 57, Issue 2, Pages (October 2000)
Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry  Takayuki Hamano, Naohiko Fujii, Terumasa.
Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.
Volume 75, Issue 9, Pages (May 2009)
Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation  A.K. Singh, D.W. Coyne,
Presentation transcript:

Medical Directorate, National Kidney Foundation, Singapore Efficacy and safety of low dose intravenous iron in ESRD patients on hemodialysis. Sreekrishna V MD, Balasubramanian S MD, Prabhakar KS MD* and Nandakumar M MD,MRCP,FAMS. Medical Directorate, National Kidney Foundation, Singapore Introduction: Conventional protocols for replacement of intravenous iron (i.v.iron) are effective but iron overload remains a major concern. We studied the outcome of short course of low dose intravenous iron in patients on hemodialysis. Methods: We retrospectively evaluated the data of patients on hemodialysis who received I.V. iron replacement during year 2003. Patients who were considered to have iron deficiency (both absolute and functional) received 500 mg of I.V. iron (Iron Sucrose 100 mg per dose) over 2 to 5 weeks duration. Complete iron profile including serum iron, ferritin and transferrin saturation (TS%) was obtained before and 2 months after completion of the therapy. Hemoglobin(Hb) was monitored 2 weekly. Any change of erythropoietin dose was noted at the end of 4 and 8 weeks Results: Sixty five patients completed the 5-course therapy. Absolute iron deficiency (ferritin <100ng/ml and TS% <20) was noted in 10%, whereas, variable numbers had some form of iron deficiency with TS%  20 in 40% and ferritin <100 ng/ml in 35%. The hemoglobin and iron profile before and after treatment was given in table below N( 65) Pre treatment One month after i.v iron Two months after i.v iron P value Hemoglobin(Hb) 9.6  1.2 10.3  1.4 10.6  1.2 P<0.001 Serum Iron 58.7  25.1   71.5  27.1 P=0.001 Transferrin Saturation 26.8  12.9 34.5  15.2 Ferritin 211.8  167.4 357.1  228.1 Only 3 (4.5%) patients have serum ferritin more than 800 ng/ml at the end of the study. However, there was no significant change in the dose of erythropoietin required. Conclusion Our study indicates that short course of relatively low dose of intravenous iron is effective in the management of anemia in patients on hemodialysis without producing iron overload. Such therapy may be safe and cost effective when given intermittently rather than high dose replacement followed by maintenance.